References in periodicals archive ?
Patients with low-grade cytomegalovirus infection had median 2-year survival rates of 63.
Vaccine prevention of maternal cytomegalovirus infection.
High incidence of active cytomegalovirus infection among septic patients.
Table 17: Cytomegalovirus Infections Market, Phase III Pipeline, 2012 42
Mycoplasma hominis Ureaplasma urealyticum Chancroid Haemophilus ducreyi> >Chlamydial infections Chlamydia trachomatis Cytomegalovirus infections Cytomegalovirus Genital herpes Herpes simplex virus Genital (venereal) warts Human papillomavirus Gonorrhea Neisseria gonorrhoeae Granuloma inguinale Calymmatobacterium granulomatis (donovanosis) Leukemia-Lymphoma/Myelopathy HTLV-I and II Lymphogranuloma venereum Chlamydia trachomatis Molluscum contagiosum Molluscum contagiosum virus Pubic lice Phthirus pubis Scabies Sarcoptes scabiei Syphilis Treponema pallidum Trichomoniasis Trichomonas vaginalis Vaginal yeast infections Candida albicans
Aviron is currently developing next generation live vaccines to prevent Influenza (Phase III), parainfluenza (Phase II 2H:97E), cytomegalovirus infections (IND 1H:98E), herpes simplex virus (preclinical), and respiratory syncycial virus (research).
Allelix products in clinical trials include ALX1-11, recombinant human parathyroid hormone, in Phase II clinical trials for the treatment of osteoporosis, and ALX40-4C in Phase I/II trials for the treatment of HIV and Cytomegalovirus infections.
PDL) (Nasdaq: PDLI) announced today that patients are being enrolled in a Phase II clinical trial of PDL's Human Anti-CMV Antibody to prevent cytomegalovirus infections in patients undergoing bone marrow transplantation.
Specifically, ongoing trials examine therapeutic strategies to prevent multiple OIs seen in the late stages of HIV infection, Pneumocystis carinli pneumonia, fungal infections common to HIV-infected women and cytomegalovirus infections.
In addition to its emerging antiviral pipeline that includes FV-100 to treat shingles (herpes zoster), HIV integrase inhibitors, HCV polymerase inhibitors and a family of compounds to address cytomegalovirus infections, the Company has several programs and collaborations based upon its proprietary MSCRAMM([R]) protein platform.